ABCC5 and prostate cancer: As shown in Figure 2, we found that the expression level of ABCC5 was significantly higher in prostate cancer patients with higher GS scores from the CPGEA cohort (p = 0.039, Figure 2A), MSKCC cohort (p = 0.046, Figure 2B), and TCGA-PRAD cohort (p < 0.001, Figure 2C) than those with low scores.